RARobert Allard

Robert Allard

*This is an algorithmically generated author record based on publicly available information.

Robert Allard has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada

    by Christina Greenaway, Laurent Azoulay, Robert Allard, Joseph Cox, Viet Anh Tran, Claire Nour Abou Chakra, Russ Steele, Marina Klein

    Immigrants originating from intermediate and high HCV prevalence countries may be at increased risk of exposure to hepatitis C infection (HCV) in their countries of origin, however they are not routinely screened after arrival in most low HCV prevalence host countries. We aimed to describe the epidemiology of HCV in immigrants compared to the Canadian born population. Using the reportable infectious disease database linked to the landed immigration database and several provincial administrative databases, we assembled a cohort of all reported cases of HCV in Quebec, Canada (1998–2008). Underlying co-morbidities were identified in the health services databases. Stratum specific rates of reported cases/100,000, rate ratios (RRs) and trends over the study period were estimated. A total of 20,862 patients with HCV were identified, among whom 1922 (9.2%) were immigrants. Immigrants were older and diagnosed a mean of 9.8 ± 7 years after arrival. The Canadian born population was more likely to have behavior co-morbidities (problematic alcohol or drug use) and HIV co-infection. Immigrants from Sub-Saharan Africa, Asia and Eastern Europe had the highest HCV reported rates with RRs compared to non-immigrants ranging from 1.5 to 1.7. The age and sex adjusted rates decreased by 4.9% per year in non-immigrants but remained unchanged in immigrants. The proportion of HCV occurring in immigrants doubled over the study period from 5 to 11%. Immigrants from intermediate and high HCV prevalence countries are at increased risk for HCV and had a mean delay in diagnosis of almost 10 years after arrival suggesting that they may benefit from targeted HCV screening and earlier linkage to care.


  • Accuracy of prospective space–time surveillance in detecting tuberculosis transmission

    by Aman Verma, Kevin Schwartzman, Marcel A. Behr, Alice Zwerling, Robert Allard, Christian M. Rochefort, David L. Buckeridge


  • Community-Acquired Clostridium difficile–Associated Diarrhea, Montréal, 2005–2006: Frequency Estimates and Their Validity

    by Robert Allard, André Dascal, Bakary Camara, Josiane Létourneau, Louise Valiquette

    A retrospective search for community-acquired Clostridium difficile-associated diarrhea in 15 hospitals revealed important discrepancies with numbers for the same period reported in real time to the surveillance system. Several of the observed problems could be solved by implementing case-by-case notification with subsequent investigation by local public health, as for other reportable diseases.


  • The reported incidence of campylobacteriosis modelled as a function of earlier temperatures and numbers of cases, Montreal, Canada, 1990–2006

    by Robert Allard, Céline Plante, Céline Garnier, Tom Kosatsky

    Previous studies have detected an effect of earlier temperatures on the incidence of campylobacteriosis in humans, but without adjustment for earlier numbers of cases of the disease. We estimated the effect of temperature on the number of cases notified by week in Montreal, Canada, from 1 January 1990 to 26 March 2006, simultaneously with the effect of the numbers of cases notified in the preceding weeks. The current campylobacteriosis count (week 0) was modelled by negative binomial regression, with earlier weekly average temperatures and earlier counts as predictors. Secular trends were accounted for by cubic spline functions and seasonal variations by sine-cosine functions. Indicator variables identified weeks with fewer than 5 working days. In the final statistical model, a 1°C increase in temperature above 10°C during any of weeks −1 to −6 was associated with a 0.8% (95% CI: 0.3% to 1.3%) increase in the current count. For each additional notified case during any of weeks −1 to −5 or −9 to −12, the increase in the current count was approximately 0.5% (95% CI: 0.2% to 1.0%). Thus, earlier temperatures and earlier counts have independent effects, that of temperatures being the larger one. The temperature effect is too small to require short term public health planning. However, in Montreal, an increase in average temperature of the order of 4.5°C, forecast by some for 2055, could produce a 23% increase in incidence, resulting in about 4,000 excess cases per year.


  • Open Access

    Diabetes and the Severity of Pandemic Influenza A (H1N1) Infection

    by Robert Allard, Pascale Leclerc, Claude Tremblay, Terry-Nan Tannenbaum

    OBJECTIVE: To confirm the existence of an increased risk of complications from influenza A (H1N1)p among patients with diabetes. RESEARCH DESIGN AND METHODS: Using data from an enhanced influenza surveillance project in Montreal, Canada, and age/sex-specific population estimates of diabetes prevalence, we estimated the risk of hospitalization among persons with diabetes. Comparing hospitalized patients admitted or not to an intensive care unit (ICU), we estimated the risk of ICU admission associated with diabetes, controlling for other patient characteristics. RESULTS: Among 239 hospitalized patients with PCR-confirmed influenza A (H1N1)p, 162 (68%) were interviewed, of whom 22 had diabetes, when 7.1 were expected (prevalence ratio 3.10 [95% CI 2.04–4.71]). The odds ratio for ICU admission was 4.29 (95% CI 1.29–14.3) among hospitalized patients with diabetes compared to those without. CONCLUSIONS: Diabetes triples the risk of hospitalization after influenza A (H1N1)p and quadruples the risk of ICU admission once hospitalized.


  • Residential address errors in public health surveillance data: A description and analysis of the impact on geocoding

    by Kate Zinszer, Christian Jauvin, Aman Verma, Lucie Bedard, Robert Allard, Kevin Schwartzman, Luc de Montigny, Katia Charland, David L. Buckeridge


  • Using causal models to show the effect of untestable assumptions on effect estimates in randomized controlled trials

    by Robert Allard, Jean-François Boivin

    Background The methods by which randomized controlled trials (RCTs) are analyzed rest on several assumptions, most of which are untestable. Purpose To show how estimates of the net effect of treatment on survival can be obtained requiring only the assumption that randomization produced equivalent groups. Methods The assumptions underlying ratio measures of effect, based on disease occurrence times (DOT) obtained from survival curves, are identified and cumulatively removed. Results The four assumptions usually made are that (1) the ratio of disease incidence rates under treatment and under reference exposure is constant over time, (2) the groups being compared are exchangeable (equivalent), (3) a subject's DOT under treatment is independent of what his DOT would have been under the reference exposure, and (4) the treatment effect, if any, is in the same direction in all subjects. Removing Assumption 4 leads to an estimator of effect resembling the etiologic fraction, but able to accommodate both causative and preventive effects. Removing all assumptions but that of exchangeability still permits the estimation, directly from the survival curves, of a range of effect magnitudes, causative or preventive, compatible with the observed DOTs. The exchangeability assumption is the easiest to meet, by randomizing enough subjects. Limitations The statistical uncertainty that affects the estimates of survival probabilities has been ignored. Taking uncertainty into account further widens the range of effects compatible with the observations. Conclusions Retaining only the exchangeability assumption allows for a range of possible treatment effects to be estimated, although it may be wide. Readers of RCT reports should understand that the determination of a point estimate of effect within this range is entirely a function of unverifiable analytic assumptions. Clinical Trials 2007; 4: 611—620. http://ctj.sagepub.com


  • Reply to the letter of Drs De Wals and De Serres

    by Robert Allard, Paul Rivest